Myostatin Deficiency in Humans: The German Baby, Liam Hoekstra, and What the Gene Does

The boy in the photo was six days old. His thigh muscles already protruded through the newborn fat layer. That child became the proof that myostatin deficiency in humans is real, not just a mouse-lab curiosity.

Myostatin deficiency in humans at a glance

The known cases are still few. Decades after the mouse "mighty mice" paper, the documented human library is small but growing.

That table is the honest universe of what we know. Most internet "myostatin deficiency" stories restate one of these four entries.

For pathway basics, read the myostatin overview and the myostatin protein primer. For drug development context, see the myostatin inhibitor drug rundown and anti-myostatin antibody primer.

The German baby: the 2004 NEJM case

This is the case that changed the field. Markus Schuelke and colleagues at Charité in Berlin published the paper in the New England Journal of Medicine in June 2004.

The mother was a former professional sprinter from a family known locally for unusual strength. Several uncles could reportedly lift heavy stones casually. The pregnancy was uneventful.

At birth, the boy weighed in around the 75th percentile, but his thigh and upper-arm muscles were strikingly visible through the newborn fat layer. Ultrasound on day six confirmed thicker quadriceps and a larger cross-sectional muscle area compared with an age-matched control infant. Testosterone, IGF-1, and glucose were normal.

Genetic sequencing identified the cause: a homozygous G to A transition in intron 1 of the MSTN gene, breaking the splice-acceptor site. The result was loss of functional myostatin protein.

By age four, the boy could hold 3-kg dumbbells out at arm's length without trembling. His ejection fraction and cardiac function remained normal. His mother carried one copy of the mutation and was visibly muscular but not exceptional.

That paper essentially proved three things in one go: MSTN regulates muscle mass in humans, the mutation is survivable, and the inheritance behaves like incomplete dominance.

Liam Hoekstra: a different mechanism, similar look

He was not the same case. Born in 2005, Liam Hoekstra appeared on early TV segments doing pull-ups as a toddler. Clinically, he showed many features of myostatin deficiency — visible muscle hypertrophy, low body fat, very high strength relative to age.

But labs reportedly found normal circulating myostatin. The working theory was a defect on the receptor side, possibly the activin type IIB receptor (ACVR2B) that myostatin signals through. If the receptor cannot bind the ligand properly, the brake on muscle growth fails in a similar way.

Public follow-ups have been thin since his childhood, partly because the family has stepped back from media. As an adult, his phenotype reportedly normalized somewhat, which fits what we know about how childhood muscle exuberance tracks differently into adulthood without continued training.

The lesson from his case is that "myostatin deficiency" is really a small family of conditions: loss of the ligand, loss of receptor function, loss of downstream signaling. The visible end result can look the same.

The 2026 UK Biobank paper: the first big dataset

This is the most important new development in 20 years. A 2026 Nature Communications study leveraged UK Biobank exome data — roughly 500,000 adults — to look at rare, predicted function-disrupting MSTN variants in a healthy adult population.

Earlier studies were too small to detect a heterozygous phenotype. With this dataset, the team showed:

• Heterozygous carriers had measurably higher appendicular lean mass.
• Carriers had higher grip strength.
• Carriers had lower adiposity (less body fat).
• The effects were graded — a partial loss of one copy gave a partial phenotype.

That last point is the headline. In mice, myostatin levels regulate muscle "across their dynamic range." Until 2026, no human dataset was big enough to confirm that humans behave similarly. Now they have.

For drug developers, that lines up with what anti-myostatin antibodies show in trials: partial reduction of myostatin gives a real but modest lean-mass increase, not a doubling.

What these people look like as adults

Honestly, we still mostly do not know. The German boy is now an adult, but the family has kept him out of the spotlight, which is reasonable.

Liam Hoekstra's adult phenotype has been described informally as "muscular but not superhuman," consistent with the pattern that childhood hypertrophy needs continued training and adequate nutrition to translate into adult strength.

The UK Biobank carriers in 2026 are healthy adults walking around with measurable but unremarkable extra muscle. They are not bodybuilders. They are people who are about 1–3 kg leaner and a few kilos stronger than peers, on average.

That gap between "Hercules" media framing and the actual lived adult experience is one of the most important corrections this article can make.

Heterozygous vs homozygous: what the difference looks like

Two copies versus one. The German baby had a homozygous mutation — both MSTN copies broken — and a striking phenotype. His mother had one broken copy and looked muscular but not unusual to a casual eye.

The pattern is similar to bovine double-muscling. Belgian Blue cattle homozygous for MSTN deletions look like grocery-store anatomy diagrams. Heterozygotes are visibly muscular but not extreme. Whippets with one copy of the bullycut variant outrun normal whippets; two copies produce a stocky, bulky build that is poor for racing.

In humans, the same pattern shows up in the 2026 data: dose-dependent, partial in heterozygotes, larger in (theoretical) homozygotes.

Do they need to lift to look that way?

Mostly yes, eventually. Childhood hypertrophy can be visible even without training, as in the German baby's case. But adult muscle still responds to use.

A person with low MSTN function who never trains will end up far less muscular than one who lifts regularly. The genetic difference acts more like a higher ceiling than a guaranteed result.

That maps onto the broader myostatin inhibitor results discussion. Inhibiting the brake helps, but only if the engine is running.

The "Hercules gene" framing: accurate vs hype

The nickname is half right. "Hercules gene" is a useful nudge for general audiences and is sometimes used in scientific commentary. But several common claims around it are exaggerated:

• "Doubles your strength" — not what the data shows. Adult human carriers gain roughly single-digit percentage points in strength, not 2x.
• "Removes all need for training" — false. Training is still required to express the muscle potential.
• "Causes superhuman physique" — overstated for heterozygotes. Homozygous cases are rare and not always studied long term.
• "Found in elite athletes" — some MSTN polymorphisms (K153R, A55T) appear at modestly different frequencies in athlete cohorts, but no single variant defines elite status.

For commercial honesty, read are myostatin inhibitors legal? and the myostatin inhibitor human guide.

Could someone test for it?

Yes, but it rarely changes life. Whole-exome or targeted MSTN sequencing can detect known function-disrupting variants. Companies like 23andMe report some common MSTN polymorphisms, though their consumer reports are limited.

For an athlete or curious adult, knowing your MSTN genotype:

• Will not change the recommended training plan.
• Will not change the recommended protein intake.
• Might explain a long-standing tendency to gain muscle easily.
• Will not predict response to a myostatin inhibitor peptide.

A clinical-grade test still requires a clinician's order in most countries, and insurance typically does not cover it for cosmetic reasons.

Health risks of low myostatin in humans

The honest answer is "still being figured out." MedlinePlus notes that documented humans with myostatin-related muscle hypertrophy have not shown medical problems and have normal intellectual development.

But the cohort is small. Concerns raised in animal data include:

• Reduced oxidative capacity in muscle (less mitochondrial density).
• Tendon stiffness and increased risk of tendon rupture.
• Possible bone density trade-offs.
• Reproductive effects via FSH — relevant given the 2025 Science paper on myostatin and pituitary signaling. See myostatin in women for more.

For someone considering pharmacological myostatin inhibition, those same trade-offs deserve a real conversation with a clinician.

What we still do not know

Open questions, in plain language:

• How adult homozygous human carriers actually live and age. The sample is still tiny.
• Whether long-term myostatin loss alters tendon and joint biology in humans.
• Whether MSTN variants meaningfully affect cardiovascular outcomes in older life.
• Whether function-disrupting variants protect from sarcopenia or carry other costs.
• How CRISPR-based MSTN editing will perform when (not if) someone tries it in humans.

Anyone who tells you these answers are settled is selling something.

Sources and notes

This article was built from DuckDuckGo and Bing SERP review, full-page competitor checks, and current evidence sources:

• Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child (NEJM 2004)
• Humans with function-disrupting variants in the myostatin gene (Nature Communications 2026)
• Myostatin-related muscle hypertrophy - MedlinePlus Genetics
• Myostatin - Wikipedia
• Myostatin-related muscle hypertrophy - Wikipedia
• Lack of myostatin results in excessive muscle growth but impaired force generation (PNAS)
• Myostatin Deficiency: When Genes Supercharge Muscles - GenesWellness

Frequently Asked Questions